KR102865751B1 - 소듐 페닐부티레이트를 포함하는 맛우수한 조성물 및 그의 용도 - Google Patents

소듐 페닐부티레이트를 포함하는 맛우수한 조성물 및 그의 용도

Info

Publication number
KR102865751B1
KR102865751B1 KR1020247025507A KR20247025507A KR102865751B1 KR 102865751 B1 KR102865751 B1 KR 102865751B1 KR 1020247025507 A KR1020247025507 A KR 1020247025507A KR 20247025507 A KR20247025507 A KR 20247025507A KR 102865751 B1 KR102865751 B1 KR 102865751B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
total weight
less
composition according
taste
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247025507A
Other languages
English (en)
Korean (ko)
Other versions
KR20240119184A (ko
Inventor
레아 이. 애펠
조슈아 알. 샤키
디. 크리스토퍼 쉘링
Original Assignee
에이서 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이서 테라퓨틱스 인크. filed Critical 에이서 테라퓨틱스 인크.
Priority to KR1020257031993A priority Critical patent/KR20250150154A/ko
Publication of KR20240119184A publication Critical patent/KR20240119184A/ko
Application granted granted Critical
Publication of KR102865751B1 publication Critical patent/KR102865751B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
KR1020247025507A 2016-03-15 2016-10-17 소듐 페닐부티레이트를 포함하는 맛우수한 조성물 및 그의 용도 Active KR102865751B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257031993A KR20250150154A (ko) 2016-03-15 2016-10-17 소듐 페닐부티레이트를 포함하는 맛우수한 조성물 및 그의 용도

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662308614P 2016-03-15 2016-03-15
US62/308,614 2016-03-15
KR1020187029452A KR102690703B1 (ko) 2016-03-15 2016-10-17 소듐 페닐부티레이트를 포함하는 맛우수한 조성물 및 그의 용도
PCT/US2016/057415 WO2017160345A1 (en) 2016-03-15 2016-10-17 Palatable compositions including sodium phenylbutyrate and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187029452A Division KR102690703B1 (ko) 2016-03-15 2016-10-17 소듐 페닐부티레이트를 포함하는 맛우수한 조성물 및 그의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257031993A Division KR20250150154A (ko) 2016-03-15 2016-10-17 소듐 페닐부티레이트를 포함하는 맛우수한 조성물 및 그의 용도

Publications (2)

Publication Number Publication Date
KR20240119184A KR20240119184A (ko) 2024-08-06
KR102865751B1 true KR102865751B1 (ko) 2025-09-29

Family

ID=59847918

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020257031993A Pending KR20250150154A (ko) 2016-03-15 2016-10-17 소듐 페닐부티레이트를 포함하는 맛우수한 조성물 및 그의 용도
KR1020187029452A Active KR102690703B1 (ko) 2016-03-15 2016-10-17 소듐 페닐부티레이트를 포함하는 맛우수한 조성물 및 그의 용도
KR1020247025507A Active KR102865751B1 (ko) 2016-03-15 2016-10-17 소듐 페닐부티레이트를 포함하는 맛우수한 조성물 및 그의 용도

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020257031993A Pending KR20250150154A (ko) 2016-03-15 2016-10-17 소듐 페닐부티레이트를 포함하는 맛우수한 조성물 및 그의 용도
KR1020187029452A Active KR102690703B1 (ko) 2016-03-15 2016-10-17 소듐 페닐부티레이트를 포함하는 맛우수한 조성물 및 그의 용도

Country Status (22)

Country Link
US (5) US20170266115A1 (enExample)
EP (2) EP4104822A1 (enExample)
JP (3) JP7136763B2 (enExample)
KR (3) KR20250150154A (enExample)
AU (1) AU2016398029B2 (enExample)
BR (1) BR112018068665B1 (enExample)
CY (1) CY1125450T1 (enExample)
DK (1) DK3429559T3 (enExample)
ES (1) ES2922749T3 (enExample)
HR (1) HRP20220856T1 (enExample)
HU (1) HUE059630T2 (enExample)
IL (3) IL296490B1 (enExample)
LT (1) LT3429559T (enExample)
MX (2) MX391305B (enExample)
PL (1) PL3429559T3 (enExample)
PT (1) PT3429559T (enExample)
RS (1) RS63383B1 (enExample)
SA (1) SA518400020B1 (enExample)
SG (1) SG11201807979SA (enExample)
SI (1) SI3429559T1 (enExample)
SM (1) SMT202200386T1 (enExample)
WO (1) WO2017160345A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3429559T3 (da) 2016-03-15 2022-07-11 Acer Therapeutics Inc Velsmagende sammensætninger indeholdende natriumphenylbutyrat og anvendelser deraf
US11583542B2 (en) * 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
WO2022011061A1 (en) * 2020-07-07 2022-01-13 Acer Therapeutics Inc. Methods of administering taste masked phenylbutyrate and compositions therefor
CN116669715A (zh) * 2020-11-18 2023-08-29 Fb-Hrs有限责任公司 含有多非利特和美西律的组合物及其应用
CN113332267A (zh) * 2021-03-31 2021-09-03 中山大学孙逸仙纪念医院 苯丁酸钠在制备预防或治疗帕金森病的药物中的应用
IT202100019613A1 (it) 2021-07-23 2023-01-23 Kolfarma S R L Formulazione farmaceutica o di integratore alimentare contenente alfa-lattoalbumina e acido butirrico o un suo sale
CN216570857U (zh) * 2021-08-11 2022-05-24 Acer治疗公司 改善药物物质适口性的剂型和多个剂型

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
AR034813A1 (es) 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
EP1291015A1 (en) 2001-09-10 2003-03-12 Lunamed AG Dosage forms having prolonged active ingredient release
US20040152784A1 (en) * 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
FR2850275B1 (fr) 2003-01-24 2005-04-08 Scherer Technologies Inc R P Capsules molles a macher contenant une substance active a gout masque
JP2005060310A (ja) 2003-08-13 2005-03-10 Towa Yakuhin Kk 不快な味をマスキングする経口投与用製剤
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
CA2561855A1 (en) * 2004-04-12 2005-10-20 Pfizer Products Inc. Taste-masked drugs in rupturing multiparticulates
WO2008148798A2 (en) * 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
ES2332687B1 (es) 2008-03-13 2011-01-10 Proyecto De Biomedicina Cima, S.L. Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
WO2010038691A1 (ja) * 2008-09-30 2010-04-08 アステラス製薬株式会社 経口投与用粒子状医薬組成物
EP2456304B1 (en) 2009-07-24 2015-08-19 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
FR2959129B1 (fr) * 2010-04-21 2013-02-01 Lucane Pharma Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations
EP2389932A1 (en) * 2010-05-28 2011-11-30 Lunamed AG Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts
EP2648528B1 (en) 2010-12-06 2016-07-20 Degama Berrier Ltd. Composition and method for improving stability and extending shelf life of probiotic bacteria and food products thereof
US8897280B2 (en) * 2011-03-29 2014-11-25 Qualcomm Incorporated System and method for clear channel assessment that supports simultaneous transmission by multiple wireless protocols
JP2012240917A (ja) 2011-05-16 2012-12-10 Zensei Yakuhin Kogyo Kk 製剤化用微粒子とそれを含む製剤
EP2709593A4 (en) * 2011-05-16 2014-10-29 Sun Pharma Advanced Res Co Ltd PHARMACEUTICAL COMPOSITION OF MULTIPLE PARTICLES
CA2838311A1 (en) 2011-06-07 2012-12-13 SPAI Group Ltd. Compositions and methods for improving stability and extending shelf life of sensitive food additives and food products thereof
JP2014517057A (ja) * 2011-06-22 2014-07-17 ジーエムピー‐オーファン 運動ニューロン疾患または代謝性疾患の治療のための直腸形態のフェニル酪酸塩
KR20140057604A (ko) 2011-08-12 2014-05-13 베링거잉겔하임베트메디카게엠베하 고양잇과 동물의 심부전을 치료 및 예방하는 방법에 사용하기 위한 퍼니 전류 억제제
EP2599477A1 (en) * 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbutyric acid sustained release formulation
US8993041B2 (en) 2012-10-15 2015-03-31 New Jersey Institute Of Technology Taste masked active pharmaceutical powder compositions and processes for making them
CN103070844A (zh) 2013-01-28 2013-05-01 万平 一种定位速释生物粘附剂及其应用
JP6147711B2 (ja) 2014-05-26 2017-06-14 富士フイルム株式会社 医薬用組成物及びその製造方法、並びに口腔内崩壊錠及びその製造方法
DK3429559T3 (da) 2016-03-15 2022-07-11 Acer Therapeutics Inc Velsmagende sammensætninger indeholdende natriumphenylbutyrat og anvendelser deraf

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Arch Dis Child. 97:1081-1085(2012.)*

Also Published As

Publication number Publication date
CA3017573A1 (en) 2017-09-21
MX2022003969A (es) 2022-04-25
WO2017160345A8 (en) 2018-02-22
AU2016398029B2 (en) 2023-03-02
ES2922749T3 (es) 2022-09-20
SMT202200386T1 (it) 2022-11-18
KR20250150154A (ko) 2025-10-17
PL3429559T3 (pl) 2022-11-07
US11154521B2 (en) 2021-10-26
MX391305B (es) 2025-03-21
JP2019509345A (ja) 2019-04-04
AU2016398029A1 (en) 2018-10-11
BR112018068665A2 (pt) 2019-02-05
IL322955A (en) 2025-10-01
IL296490B1 (en) 2025-09-01
IL261777B2 (en) 2023-02-01
CY1125450T1 (el) 2025-05-09
LT3429559T (lt) 2022-08-10
EP3429559B1 (en) 2022-04-13
JP7136763B2 (ja) 2022-09-13
DK3429559T3 (da) 2022-07-11
EP4104822A1 (en) 2022-12-21
SG11201807979SA (en) 2018-10-30
JP2024081748A (ja) 2024-06-18
US20210186908A1 (en) 2021-06-24
HUE059630T2 (hu) 2022-11-28
WO2017160345A1 (en) 2017-09-21
US20210220304A1 (en) 2021-07-22
KR102690703B1 (ko) 2024-08-02
MX2018011229A (es) 2019-05-30
US20170266115A1 (en) 2017-09-21
RS63383B1 (sr) 2022-08-31
US20200261385A1 (en) 2020-08-20
SA518400020B1 (ar) 2022-12-21
EP3429559A4 (en) 2019-11-06
IL261777A (en) 2018-10-31
EP3429559A1 (en) 2019-01-23
HRP20220856T1 (hr) 2022-10-14
PT3429559T (pt) 2022-07-20
US11433041B2 (en) 2022-09-06
KR20190008840A (ko) 2019-01-25
SI3429559T1 (sl) 2022-11-30
JP2022106927A (ja) 2022-07-20
KR20240119184A (ko) 2024-08-06
IL296490A (en) 2022-11-01
US20230133629A1 (en) 2023-05-04
US11202767B2 (en) 2021-12-21
BR112018068665B1 (pt) 2023-12-26
IL261777B (en) 2022-10-01

Similar Documents

Publication Publication Date Title
US11202767B2 (en) Methods of treating urea cycle disorders and maple syrup urine disease
EP1940361B1 (en) Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20100203119A1 (en) Pharmaceutical treatment process using chitosan or derivative thereof
EP3821881A1 (en) Delayed release compositions of linaclotide
CN105682648A (zh) 用于以低的日剂量施用的含富马酸二甲酯的药物组合物
JP2002527468A (ja) 脈動用量薬剤経口送達システム
WO2013009186A1 (en) Nicotinamide compositions and the therapeutic use thereof
JP2022549137A (ja) イブジラスト経口製剤およびその使用方法
CA3017573C (en) Palatable compositions including sodium phenylbutyrate and uses thereof
KR20190131036A (ko) 비-사람 포유동물에게 마이코페놀산 활성제를 전달하기 위한 방법 및 조성물
US20220241367A1 (en) Treatment of Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome
EP4525856A1 (en) Rifaximin and n-acetyl cysteine formulations

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)